CA2773611A1 - Use of guaifenesin for inhibiting mucin secretion - Google Patents

Use of guaifenesin for inhibiting mucin secretion Download PDF

Info

Publication number
CA2773611A1
CA2773611A1 CA2773611A CA2773611A CA2773611A1 CA 2773611 A1 CA2773611 A1 CA 2773611A1 CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A CA2773611 A CA 2773611A CA 2773611 A1 CA2773611 A1 CA 2773611A1
Authority
CA
Canada
Prior art keywords
composition
guaifenesin
administering
effective amount
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2773611A
Other languages
English (en)
French (fr)
Inventor
Helmut Albrecht
K. Chul Kim
Jeanclare Seagrave
Bruce K. Rubin
Gail Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RB Health US LLC
Original Assignee
Reckitt Benckiser LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser LLC filed Critical Reckitt Benckiser LLC
Publication of CA2773611A1 publication Critical patent/CA2773611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2773611A 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion Abandoned CA2773611A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
US12/558,517 2009-09-12
GB1002039.4 2010-02-09
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
CA2773611A1 true CA2773611A1 (en) 2011-03-17

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773611A Abandoned CA2773611A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Country Status (12)

Country Link
EP (1) EP2475360A1 (ja)
JP (1) JP2013504554A (ja)
KR (1) KR20120068889A (ja)
CN (1) CN102596189A (ja)
AU (1) AU2010294008B2 (ja)
BR (1) BR112012005517A2 (ja)
CA (1) CA2773611A1 (ja)
MX (1) MX2012003042A (ja)
MY (1) MY161187A (ja)
RU (1) RU2012114323A (ja)
WO (1) WO2011030163A1 (ja)
ZA (1) ZA201201822B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619321A (zh) * 2012-04-06 2015-05-13 Uab研究基金会 用于增加cftr活性的方法
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
JP2005519923A (ja) * 2002-02-04 2005-07-07 ファルマシア・コーポレーション シクロオキシゲナーゼ−２選択的阻害剤ならびに風邪および咳止め薬の組み合わせを用いる風邪および咳の治療ならびにそれらの組成物
KR20060056444A (ko) * 2003-06-19 2006-05-24 제내라 코포레이션 뮤신 합성 억제제
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
MY161187A (en) 2017-04-14
BR112012005517A2 (pt) 2016-04-19
ZA201201822B (en) 2013-05-29
RU2012114323A (ru) 2013-10-20
MX2012003042A (es) 2012-05-29
KR20120068889A (ko) 2012-06-27
EP2475360A1 (en) 2012-07-18
JP2013504554A (ja) 2013-02-07
CN102596189A (zh) 2012-07-18
WO2011030163A1 (en) 2011-03-17
AU2010294008B2 (en) 2014-08-14
AU2010294008A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
Weidner et al. Potassium paraaminobenzoate (POTABA™) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study
Caldwell et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis
Murti et al. Etiology of oral submucous fibrosis with special reference to the role of areca nut chewing
US20120322719A1 (en) Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
KR20160113307A (ko) 당뇨병 및 간 질환의 치료를 위한 조성물들 및 방법들
Wen et al. Denatonium inhibits growth and induces apoptosis of airway epithelial cells through mitochondrial signaling pathways
CA2773611A1 (en) Use of guaifenesin for inhibiting mucin secretion
Malo et al. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis
Ara et al. Correlation of habits and clinical findings with histopathological diagnosis in oral submucosal fibrosis patients
TW201609111A (zh) 人參皂苷ｍ１用於抑制腎纖維化之用途
Namba et al. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes
Shih et al. Effect ofAnoectochilus formosanuson fibrosis and regeneration of the liver in rats.
Wu et al. Paeoniflorin confers ferroptosis resistance by regulating the gut microbiota and its metabolites in diabetic cardiomyopathy
Asifali et al. Frequency and clinical presentation of oral submucous fibrosis
Mattoli et al. Nedocromil sodium prevents the release of 15-hydroxyeicosatetraenoic acid from human bronchial epithelial cells exposed to toluene diisocyanate in vitro
US20110065744A1 (en) Method Of Inhibiting Mucin Secretion
Dobrek et al. Urinary kidney injury molecule-1 (KIM-1) excretion in rats with experimental cystitis induced by oxazaphosphorines
CN117157063A (zh) 用于治疗癌症和癌前乳头瘤病毒病变的2-s金刚乙胺和2-r金刚乙胺
UA47505C2 (uk) Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
EP3863643A1 (en) Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions
US20240295566A1 (en) Method for diagnosing and treating metabolic disorders
US20240307361A1 (en) Method for diagnosing and treating irritable bowel syndrome
Maritzen et al. ClC-5 does not affect megalin expression and function in the thyroid
KR102617037B1 (ko) 폐암 재발 예측방법 및 재발 억제용 약학적 조성물
Hisamatsu et al. Effect of leukotriene C4 exposure on ciliated cells of the nasal mucosa

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150820

FZDE Discontinued

Effective date: 20190514